Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc.

MLYS·NASDAQ

$25.06

-19%
HealthcareBiotechnology

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.66B
EPS-2.2900
P/E Ratio-10.94
Earnings Date08/11/2026

No Dividend Yield Data

MLYS has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

MLYS has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

MLYS has not reported any net dividends paid values in the available annual periods.

Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. Dividend History

MLYS · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

MLYS Dividend Payment History

MLYS · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
mlys

Mineralys Therapeutics, Inc. Payout Ratio Analysis

MLYS · NASDAQ
Dividends Paid
0.00
2025
Net Income
-154.65M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.